Prescient Therapeutics (PTX) has unveiled a novel adjuvant for enhancing cellular immunotherapy.
The CellPryme-A product was designed to be administered to cancer patients as an intravenous infusion in combination with cellular immunotherapy, such as PTX’s CAR-T cell therapy. This is used to address the hostile tumour microenvironment that cellular immunotherapies face.
CellPryme-A can be administered either before or alongside cellular immunotherapy.
Prescient said in animal models, CellPryme-A had been shown to reduce the number of suppressive regulatory T cells surrounding solid tumours that counteracted the effectiveness of CAR-T and other cancer therapies.
While CellPrymeA demonstrated superior tumour killing and host survival in pre-clinical studies, its effects were even greater when used together with Prescient’s CAR-T manufacturing technology, CellPryme-M.
The company presented this new data at the seventh annual CAR-TCR Summit in Boston.
Prescient Managing Director and CEO Steven Yatomi-Clarke said the company was delighted to “finally” unveil CellPryme-A as a distinct but complementary addition to CellPryme-M.
“Together with Prescient’s next-generation CAR platform, OmniCAR, Prescient has placed itself enviably at the forefront of cellular immunotherapy by creating technologies that overcome the challenges facing the field,” Mr Yatomi-Clarke said.
The company said CellPryme-Awas now ready for clinical testing and could be incorporated into clinical studies of existing cell therapies.
Prescient Therapeutics was down 1.35 per cent and trading at 18 cents at 1:29 pm AEST.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.